HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

Overview of attention for article published in Investigational New Drugs, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 7,393 followers.

RT @cdanicas: HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic CRPC. http://t.co/pUEXmTQUoq #springerlink

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic CRPC. http://t.co/pUEXmTQUoq #springerlink